UK Announces New Five-Year Voluntary Drug Pricing Deal

 
• By Ian Schofield

The VPAG includes a gradual rise in allowable branded medicine sales to the NHS and differentiated payment mechanisms for older and newer products. Industry will also commit to invest £400m in “pioneering” clinical trials, innovative manufacturing, and novel approaches to health technology assessments.

Blue & Orange drug medicine pills colored capsules closeup with pound coin on white background
The UK industry has agreed a new five-year drug pricing deal • Source: Shutterstock

More from Europe

More from Geography